Conducting clinical research studies with
SKILL, KNOWLEDGE and SAFETY.
Call to participate
860.443.4567

Archive for the ‘ Dr. McDermott ’ Category

Migraine Headaches

Thursday, May 25th, 2017

For years, Susan had been living with incapacitating headaches that sometimes caused her to miss work or family events.  The headaches began in her late teens and have lasted until now, her mid-30’s.  Sometimes the headaches would start on a Monday and stretch all the way until Wednesday.  Quite frequently with these headaches Susan would experience nausea, as well as sensitivity to lights and sounds.  When these headaches came on, Susan would turn off all the lights, avoid people and hunker down.  What Susan did not realize is her headaches were in fact migraines!

Not everyone who lives with migraine headaches realize they are in fact getting a migraine.  3 million Americans are currently suffering with this condition.  Vision can become blurred, people can experience fatigue, stomach upset, and intense, throbbing pain.

Research is underway in New London testing an investigational medication for the prevention of migraine headaches. Dr. Laurence Radin, Dr. Edward McDermott, and Andrea Stewart APRN are members of a  Migraine Prevention Study  research team in New London. Individuals living with migraine headaches who may wish to learn more about this 9-month research study are welcome to call to speak with a member of the CCRstudies team at (860) 443-4567 or email marylou@ccrstudies.com.

 

Alzheimer’s Study

Wednesday, November 25th, 2015

STARBEAM STUDY Postcard CCR

Alzheimer’s is a progressive disease of the brain. Brian cells die over a period of several years, and symptoms progress from mild to severe.  Alzheimer’s is one of the leading causes of death in the U.S., and affects over 5 million Americans.

It has been over a decade since the FDA has approved any new medications for the treatment of Alzheimer’s.  Clinical research is currently underway in New London at CCRstudies, testing an investigational add-on medication. The team of investigators includes Laurence Radin, MD, Edward McDermott, Jr., MD, and Andrea Stewart, APRN.   This medication is taken in conjunction with the study patients current dosage of Aricept (Donepezil.)  The investigational medication is designed to improve thinking, memory, reasoning and cognition.  It is the Phase 3 of the clinical trial process.

Those interested in learning more about the Alzheimer’s study underway in New London can contact a member of the CCRstudies team at (860)443-4567, or click on this link for further details  https://www.youtube.com/watch?v=l1LgVnQ3pqU.

In addition to the study patient, caregivers play an important role in this trial.  There is no cost to participate and compensation is available for time and travel to the study patient and caregiver.

Alzheimer’s Awareness

Friday, October 30th, 2015
CCRstudies is a member of the Alzheimer's Foundation of America.

CCRstudies is a member of the Alzheimer’s Foundation of America.

November is National Alzheimer’s Awareness Month. Volunteers are needed for an Alzheimer’s study being conducted in New London by Dr. Laurence Radin, Dr. Edward McDermott, and Andrea Stewart, APRN.

Alzheimer’s disease is the most common form of dementia in adults 65 and over.  Dementia is a general term which describes a group of symptoms related to the loss of a variety of intellectual functions.  This can include loss in memory, judgment, language and complex motor skills which may interfere with daily living.

The Alzheimer’s Foundation of America notes that “Alzheimer’s disease is not a normal part of aging: however, age is the greatest known risk factor.  Other factors are genetic makeup and chronic untreated health problems such as high blood pressure.”

There is no cure currently available for Alzheimer’s disease, but there are FDA-approved medications available that can help to slow the progression of disease symptoms.

Research is currently underway in New London testing an investigational add-on medication for the treatment of Alzheimer’s. Volunteers with mild to moderate memory loss currently taking Aricept are needed as potential study volunteers. There has been no new medication introduced for the treatment of Alzheimer’s in over a decade.  If you or someone you know, ages 50 or above, is living with mild to moderate memory loss, you may qualify for this research study.  Call a member of the CCRstudies Team at 860-443-4567 today to learn more about how you can be involved in research.  Study participants and caregivers are eligible to receive compensation for their time and travel in addition to no cost study-related care.

Alzheimer’s Talk on the Air

Monday, August 31st, 2015

Recently, CCRstudies had the good fortune of going on the Lee Elci Radio Show on 94.9 News Now.  Lee, an affable host, allowed CCR’s MaryLou Gannotti, Public Relations and Communications Director, to have an open discussion on Alzheimer’s Disease, including promoting CCRstudies no cost memory testing through the Alzheimer’s Foundation of America. MaryLou also talked about the STARBEAM study, a clinical research trial testing an investigation add-on medication for those living with mild to moderate Alzheimer’s Disease.

To hear more, click on the play button below:

To learn more about CCRstudies Free Memory Testing, or the STARBEAM study, call 860-443-4567 or email marylou@ccrstudies.com.

DPN Study

Monday, May 4th, 2015

Over half of all those living with Type II Diabetes will develop DPN.

DPN, or Diabetic Peripheral Neuropathy, is a condition that results due to chronically high blood sugar levels resulting in nerve damage.  Symptoms of DPN can include pain, numbness and tingling in the feet, discomfort, and burning sensations.  Due to nerve damage, complications can arise for the individual living with DPN.

Diabetes has been described as a global epidemic, with nearly 26 million Americans living with the condition. Poor diet, lack of exercise, and increasing obesity rates are often to blame for the Type II diabetes crisis in the US.

CCRstudies has been enrolling eligible volunteers for a study looking at the effectiveness of a nutritional food in the treatment of diabetic foot pain.  The nutritional therapy, Metanx, is a FDA approved medication containing a combination of the active forms of folic acid, vitamin B6 and vitamin B12. These vitamins are said to work together to increase blood flow to the nerves.

Metanx differs from standard over the counter vitamins since it is considered a “medical food.” Medical foods have been specially formulated to address distinct nutritional requirements of a specific disease or condition. Metanx is only available by prescription.

The study team consists of Edward J. McDermott, Jr MD, Laurence Radin MD, Andrea Stewart, APRN, Diane Palmer, RN, CCRC, Jessie Jellison, LPN, CRC and Carol Alexandrescu, MS, CRC.

Those interested in learning more about the DPN study can call 860-443-4567.

Medical Food for DPN

Tuesday, August 12th, 2014

They say “you are what you eat,” and an “apple a day keeps the doctor away.”   You most certainly have heard of these common expressions!  For centuries, there has been a link between good food and good health.  That link has been strengthened even more thanks to the introduction of “medical food.” CCRStudies is currently conducting a clinical trial on Diabetic Neuropathy (DPN) that tests the results of a medical food called Metanx. The purpose of the “medical food” is to decrease the tingling, burning sensations and numbness in the feet caused by those living with DPN.   Metanx is a multivitamin containing a combination of folic acid, vitamin B6 and vitamin B12.  These vitamins work together to increase to blood flow to the nerves in patients living with diabetic peripheral neuropathy, which develops as a result of chronically high blood sugar levels.   Diabetes has become a global epidemic, and currently about 26 million Americans are living with the disease.  As these numbers continue to rise, so do the numbers of those living with the discomfort of DPN, which, if left untreated, can lead to further complications.

The study team includes Edward J. McDermott, Jr., MD; Laurence Radin, MD; Andrea Bartels APRN; Andrea Stewart APRN; Diane Palmer, RN, CCRC, Jessie Jellison, LPN, CRC; and Carol Alexandrescu, MS, CRC.

Diabetic Neuropathy Research Study

Tuesday, June 17th, 2014

Do you have numb, tingling painful feet due to DPN?

CCRstudies is seeking individuals to participate in Diabetic Peripheral Neuropathy (DPN) research study of Matanx in addressing DPN symptoms.

To qualify you must:

Be between the ages of 25 to 80

Have a diagnosis of Type II Diabetes

Have established DPN for over 6 months but less than 7 years

Qualified participants will receive at no cost, study related:

Investigational medication or placebo

Diagnostic and routine lab testing at no cost.

For more information call: 860-443-4567